关注公众号
收藏产品 产品详情
特异性（Specificity）
Specifically recognizes PBD.
抗体来源（Source）
Monoclonal Anti-Payload PBD Antibody, Rabbit IgG (1M1F9) is a Rabbit monoclonal antibody recombinantly expressed from HEK293 cells.
克隆号（Clone）
1M1F9
亚型（Isotype）
Rabbit IgG | Rabbit Kappa
偶联（Conjugate）
Unconjugated
免疫原（Immunogen）
PBD-BSA.
应用（Application）
ApplicationRecommended UsageELISA0.06-10000 ng/mL纯化（Purification）
Protein A purified / Protein G purified
制剂（Formulation）
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重构方法（Reconstitution）
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存储（Storage）
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
质量管理控制体系（QMS）
数据展示
活性（Bioactivity）-ELISA
Immobilized Monoclonal Anti-Payload PBD Antibody, Rabbit IgG (1M1F9) (Cat. No. PAD-MY2212) at 1 μg/mL, add Loncastuximab Tesirine in the 100% Human Serum and then add Biotinylated Human CD19 (20-291), His,Avitag, premium grade (Cat. No. CD9-H82E9) at 0.5 μg/mL. Detection was performed using HRP-conjugated Streptavidin (Acro, Cat. No. STN-NH913) (QC tested).
Protocol
Serial dilutions of (PBD)SG3199 were added into Monoclonal Anti-Payload PBD Antibody, Rabbit IgG (1M1F9) (Cat. No. PAD-MY2212)): Loncastuximab Tesirine binding reactions. The half maximal inhibitory concentration (IC50) is 0.02167 μg/mL (Routinely tested).
Protocol
交叉验证-Cross Verification
ELISA binding of Monoclonal Anti-Payload PBD Antibody, Rabbit IgG (1M1F9) (Cat. No. PAD-MY2212) with Loncastuximab Tesirine, Disitamab Vedotin (RC48), IgG1-MMAF, Trastuzumab Deruxtecan, Sacituzumab Govitecam and Trastuzumab-DM1 conjugated antibody respectively.
The coating antibody was Monoclonal Anti-Payload PBD Antibody, Rabbit IgG (1M1F9) (Cat. No. PAD-MY2212), used at 1 μg/mL concentration. The primary antibody were different payload conjugated antibodies, including Loncastuximab Tesirine, Disitamab Vedotin (RC48), IgG1-MMAF, Trastuzumab Deruxtecan, Sacituzumab Govitecam and Trastuzumab-DM1 conjugated antibodies used at 0.25 μg/mL concentration. The secondary antibody was HRP conjugated Anti-Human-IgG-Fc Antibody (6F11C8), mAb (Acro, Cat. No. IGG-LY69) used at 1:10000 concentration.
Monoclonal Anti-Payload PBD Antibody, Rabbit IgG (1M1F9) (Cat. No. PAD-MY2212) is specific to Loncastuximab Tesirine and has no cross-reactivity with IgG1-MMAF, Disitamab Vedotin (RC48), Trastuzumab Deruxtecan, Sacituzumab Govitecam and Trastuzumab-DM1 (Routinely tested).
用户评价 发表评论
联系我们 
项目合作